CN Patent

CN104370811B — 一种喹啉化合物的新晶型及其制备方法

Assigned to Guangdong HEC Pharmaceutical Co Ltd · Expires 2019-02-12 · 7y expired

What this patent protects

本发明涉及一种喹啉化合物的新晶型及其制备方法，属于药物化学领域。所述新晶型的X‑射线粉末衍射图中在2θ大约为11.9,12.9,14.4,16.0,22.1,26.0度的位置有峰；或X‑射线粉末衍射图中在2θ大约为11.6,14.1,18.5,21.1,22.2,23.2,24.1,29.0度的位置有峰。所述具备较好的稳定性和流动性，有利于储存、转移、生产中操作，可用于制备其药学上可接受的盐而运用于制剂。

USPTO Abstract

本发明涉及一种喹啉化合物的新晶型及其制备方法，属于药物化学领域。所述新晶型的X‑射线粉末衍射图中在2θ大约为11.9,12.9,14.4,16.0,22.1,26.0度的位置有峰；或X‑射线粉末衍射图中在2θ大约为11.6,14.1,18.5,21.1,22.2,23.2,24.1,29.0度的位置有峰。所述具备较好的稳定性和流动性，有利于储存、转移、生产中操作，可用于制备其药学上可接受的盐而运用于制剂。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN104370811B
Jurisdiction: CN
Classification: —
Expires: 2019-02-12
Drug substance claim: No
Drug product claim: No
Assignee: Guangdong HEC Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.